Drug Safety in Diabetes

Co-Moderator(s)

• 

  Almut Winterstein, PhD

  Distinguished Professor
  University of Florida, Pharmaceutical Outcomes & Policy and Center for Drug Evaluation and Safety
  Gainesville, United States
• 

  Christian Hampp, PhD, FISPE (he/him/his)

  Director, Pharmacoepidemiology
  Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  Tarrytown, United States

Presentations:

• 1:00 PM – 1:15 PM ADT

  Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Fractures in Postmenopausal Women with Type 2 Diabetes: A Nationwide Cohort Study
  

  Presenting Author: Hwa Yeon Ko, PharmD – School of Pharmacy, Sungkyunkwan University
• 1:15 PM – 1:30 PM ADT

  Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A Post-Authorization Safety Study
  

  Presenting Author: Soulmaz Fazeli Farsani, PharmD, Msc, PhD – Boehringer Ingelheim International GmbH
• 1:30 PM – 1:45 PM ADT

  Insulin use in type 2 diabetes and the risk of dementia: A comparative population-based cohort study
  

  Presenting Author: Wajd Alkabbani, MSc – University of Waterloo
• 1:45 PM – 2:00 PM ADT

  Fluoroquinolones and the risk of severe hypoglycemia among sulfonylurea users
  

  Presenting Author: Jenny Dimakos, BSc (she/her/hers) – Department of Medicine, McGill University, Montreal, QC, Canada
• 2:00 PM – 2:15 PM ADT

  Dipeptidyl Peptidase-4 Inhibitors and the Risk of Biliary Tract Diseases Among Patients With Type 2 Diabetes
  

  Presenting Author: Samantha B. Shapiro, MSc, BSc – McGill University
• 2:15 PM – 2:30 PM ADT

  Ambient Heat, Exogenous Insulin, and Risk of Hypoglycemia Among Older Medicare Beneficiaries with Diabetes
  

  Presenting Author: Soko Setoguchi, MD, DrPH, FISPE – Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ